Recently, the China National Intellectual Property Administration (CNIPA) issued a Notice of Closure of Invalidation Proceedingfor the invalidation case with case number 4W112958 (hereinafter “this case”), informing the patentee Denka Co., Ltd. that the requester in this invalidation proceeding, Chongqing Zhongyuan Biotechnology Co., Ltd., submitted on February 11, 2022, a request to withdraw its invalidation petition against Chinese Invention Patent No. ZL201410058250.0 owned by Denka Co., Ltd. (invention title: “Method and Kit for Quantitative Determination of Small Dense LDL Cholesterol”, hereinafter “the present patent”). The trial of this case has thus concluded.

Beijing Caihe Law Firm was entrusted by Denka Co., Ltd. to act as the patentee’s representative in the above invalidation proceeding.

Key highlights of the case:

Prior to this case, Chongqing Zhongyuan Biotechnology Co., Ltd. and Baiding Bioengineering (Beijing) Co., Ltd. had separately filed invalidation requests with CNIPA against the present patent. After examination, CNIPA issued two invalidation examination decisions, both of which upheld the validity of the present patent.